Amneal Pharmaceuticals Reports Strong Q4 & FY25 Results, Issues Positive 2026 Guidance

summarizeSummary

Amneal Pharmaceuticals announced strong Q4 and full-year 2025 financial results, exceeding prior guidance, and provided positive 2026 financial outlook.

check_boxKey Events

• Strong Q4 2025 Performance

  Reported $814 million in net revenue, an 11% increase year-over-year, and a significant turnaround to $35 million GAAP net income from a net loss in the prior year. Adjusted diluted EPS rose to $0.21.

• Full Year 2025 Exceeds Guidance

  Achieved $3.02 billion in net revenue and $72 million in GAAP net income, surpassing previous expectations and marking a substantial improvement from a net loss in 2024. Adjusted diluted EPS reached $0.83.

• Positive 2026 Financial Guidance

  Projected 2026 net revenue between $3.05 billion and $3.15 billion, Adjusted EBITDA of $720 million to $760 million, and Adjusted Diluted EPS of $0.93 to $1.03, indicating continued growth.

• Operational Momentum

  Highlighted strong uptake of CREXONT® and successful launch of BREKIYA® autoinjector in Specialty, alongside new product approvals including inhalation products and biosimilars in Affordable Medicines.

auto_awesomeAnalysis

Amneal Pharmaceuticals delivered robust financial results for Q4 and full year 2025, successfully transitioning from a net loss to net income. The company also provided optimistic 2026 guidance, projecting continued growth in net revenue, Adjusted EBITDA, and Adjusted Diluted EPS, signaling sustained operational strength and strategic execution. This report confirms the company's earlier anticipation of meeting or exceeding 2025 guidance and sets a positive outlook for the coming year.